Citations Report
Clinical Schizophrenia & Related Psychoses : Citations & Metrics Report
Articles published in Clinical Schizophrenia & Related Psychoses have been cited by esteemed scholars and scientists all around the world. Clinical Schizophrenia & Related Psychoses has got h-index 41, which means every article in Clinical Schizophrenia & Related Psychoses has got 41 average citations.
Following are the list of articles that have cited the articles published in Clinical Schizophrenia & Related Psychoses.
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total published articles |
105 | 141 | 28 | 8 | 28 |
Conference proceedings |
0 | 0 | 0 | 0 | 0 |
Citations received as per Google Scholar, other indexing platforms and portals |
543 | 553 | 590 | 563 | 587 |
Journal total citations count | 6601 |
Journal impact factor | 6.49 |
Journal 5 years impact factor | 12.17 |
Journal cite score | 11.19 |
Journal h-index | 41 |
Journal h-index since 2019 | 26 |
Li, HuaFang, Ibrahim Turkoz, and Fan Zhang. "Efficacy and safety of once-monthly injection of paliperidone palmitate in hospitalized Asian patients with acute exacerbated schizophrenia: an open-label, prospective, noncomparative study." Neuropsychiatric disease and treatment 12 (2016): 15. |
|
González-Rodríguez, Alexandre, Rosa Catalán, Rafael Penadés, Clemente Garcia-Rizo, Miquel Bioque, Eduard Parellada, and Miquel Bernardo. "Profile of paliperidone palmitate once-monthly long-acting injectable in the management of schizophrenia: long-term safety, efficacy, and patient acceptability–a review." Patient preference and adherence 9 (2015): 695. |
|
Cano-Baena, Ana Isabel, Laura García-Ayala, Marta Zubía-Martín, Iñaki Zorrilla-Martínez, and Ana González-Pinto Arrillaga. "Schizophrenia and Gender." In Psychopathology in Women, pp. 715-737. Springer, Cham, 2019. |
|
Correll, Christoph U., Robert E. Litman, Yuriy Filts, Jordi Llaudó, Dieter Naber, Ferran Torres, and Javier Martínez. "Efficacy and safety of once-monthly Risperidone ISM® in schizophrenic patients with an acute exacerbation." npj Schizophrenia 6, no. 1 (2020): 1-9. |
|
Citrome, Leslie. "Long-acting injectable antipsychotics: what, when, and how." CNS spectrums 26, no. 2 (2021): 118-129. |
|
Janicak, Philip G. "Acute management of schizophrenia." In Schizophrenia, pp. 107-138. Springer, New York, NY, 2014. |
|
Clark, Ivana, and David Taylor. "Newer formulations of risperidone: role in the management of psychotic disorders." CNS drugs 34 (2020): 841-852. |
|
Suzuki, Takefumi. "A further consideration on long-acting injectable versus oral antipsychotics in the treatment of schizophrenia: a narrative review and critical appraisal." Expert opinion on drug delivery 13, no. 2 (2016): 253-264. |
|
Cummings, Michael A., George J. Proctor, and Ai-Li W. Arias. "Dopamine antagonist antipsychotics in diverted forensic populations." CNS spectrums 25, no. 2 (2020): 128-135. |
|
Hodgetts, Sophie, and Markus Hausmann. "Antipsychotic effects of sex hormones and atypical hemispheric asymmetries." Cortex 127 (2020): 313-332. |
|
Chue, Pierre. "Risperidone long-acting injection." (2016). |
|
Citrome, Leslie, and Jan Volavka. "Specific anti-hostility effects of atypical antipsychotics in persons with schizophrenia: from clozapine to cariprazine." Harvard review of psychiatry 29, no. 1 (2021): 20-34. |
|
Peters, Luisa, Amanda Krogmann, Laura von Hardenberg, Katja Bödeker, Viktor B. Nöhles, and Christoph U. Correll. "Long-acting injections in schizophrenia: a 3-year update on randomized controlled trials published January 2016–March 2019." Current psychiatry reports 21, no. 12 (2019): 1-31. |
|
Hodgetts, Sophie, and Markus Hausmann. "Antipsychotic effects of sex hormones and atypical hemispheric asymmetries." Cortex 127 (2020): 313-332. |
|
Orsolini, Laura, Domenico De Berardis, and Umberto Volpe. "Up-to-date expert opinion on the safety of recently developed antipsychotics." Expert Opinion on Drug Safety 19, no. 8 (2020): 981-998. |
|
Sentissi, Othman, Maria A. Andreou, Clotilde Moeglin, Logos Curtis, and Micaela Santos Brosch. "Psychosis Risk Syndrome: What Now?." Journal of Psychiatric Practice® 23, no. 6 (2017): 415-424. |
|
de Leon, Jose. "Personalizing dosing of risperidone, paliperidone and clozapine using therapeutic drug monitoring and pharmacogenetics." Neuropharmacology 168 (2020): 107656. |
|
Schoretsanitis, Georgios, John M. Kane, Christoph U. Correll, Stephen R. Marder, Leslie Citrome, John W. Newcomer, Delbert G. Robinson et al. "Blood levels to optimize antipsychotic treatment in clinical practice: a joint consensus statement of the American society of clinical psychopharmacology and the therapeutic drug monitoring task force of the arbeitsgemeinschaft für neuropsychopharmakologie und pharmakopsychiatrie." The Journal of Clinical Psychiatry 81, no. 3 (2020): 0-0. |
|
Miyamoto, Seiya, and W. Wolfgang Fleischhacker. "The use of long-acting injectable antipsychotics in schizophrenia." Current treatment options in psychiatry 4, no. 2 (2017): 117-126. |
|
Onaolapo, A. Y., and O. J. Onaolapo. "Schizophrenia aetiology and drug therapy: A tale of progressive demystification and strides in management." Adv Pharmacol Pharm 6, no. 2 (2018): 19-42. |
|